Zai Lab (NASDAQ:ZLAB) CFO Yajing Chen Sells 853 Shares

Key Points

• CFO Yajing Chen sold 853 shares of Zai Lab on April 6 at an average price of $20.45 for $17,443.85 to cover tax withholding from vested equity, leaving her with 31,705 shares (a 2.62% ownership decline).
• Chen also sold 5,199 shares on April 2 at $20.39 and 1,703 shares on March 13 at $18.63, indicating multiple recent insider dispositions.
• Zai Lab shares traded up 1.9% to $21.39 amid above-average volume; analysts remain mixed but the consensus is a “Moderate Buy” with a $50 average target despite recent negative EPS (quarterly loss of $0.50 and a -2.58 EPS forecast for the year).

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Get Free Report) CFO Yajing Chen sold 853 shares of Zai Lab stock in a transaction that occurred on Monday, April 6th. The shares were sold at an average price of $20.45, for a total transaction of $17,443.85. Following the sale, the chief financial officer owned 31,705 shares of the company's stock, valued at approximately $648,367.25. The trade was a 2.62% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Yajing Chen also recently made the following trade(s):

• On Thursday, April 2nd, Yajing Chen sold 5,199 shares of Zai Lab stock. The shares were sold at an average price of $20.39, for a total transaction of $106,007.61.
• On Friday, March 13th, Yajing Chen sold 1,703 shares of Zai Lab stock. The stock was sold at an average price of $18.63, for a total transaction of $31,726.89.

Zai Lab Trading Up 1.9%

Shares of ZLAB traded up $0.39 during mid-day trading on Wednesday, reaching $21.39. The company's stock had a trading volume of 1,059,583 shares, compared to its average volume of 745,229. The stock has a market cap of $2.41 billion, a PE ratio of -13.29 and a beta of 0.86. Zai Lab Limited Unsponsored ADR has a 52 week low of $15.96 and a 52 week high of $44.34. The company's fifty day moving average price is $18.89 and its two-hundred day moving average price is $21.51.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last announced its quarterly earnings data on Saturday, February 14th. The company reported ($0.50) earnings per share for the quarter. The business had revenue of $127.60 million during the quarter. Zai Lab had a negative return on equity of 22.81% and a negative net margin of 38.15%. Research analysts anticipate that Zai Lab Limited Unsponsored ADR will post -2.58 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the stock. UBS Group began coverage on shares of Zai Lab in a report on Wednesday, January 7th. They issued a "buy" rating and a $35.00 price objective for the company. Cantor Fitzgerald lowered their price target on shares of Zai Lab from $55.00 to $37.00 and set an "overweight" rating for the company in a report on Friday, February 27th. Jefferies Financial Group upgraded shares of Zai Lab to a "strong-buy" rating in a report on Monday, January 19th. JPMorgan Chase & Co. lowered their price target on shares of Zai Lab from $39.00 to $32.00 and set an "overweight" rating for the company in a report on Wednesday, March 18th. Finally, Zacks Research lowered shares of Zai Lab from a "hold" rating to a "strong sell" rating in a report on Friday, January 23rd. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $50.00.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Zai Lab stock. SG Americas Securities LLC acquired a new stake in shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Free Report) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 9,754 shares of the company's stock, valued at approximately $331,000. 41.65% of the stock is owned by hedge funds and other institutional investors.

Zai Lab Company Profile

Zai Lab Ltd NASDAQ: ZLAB is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company's end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company's marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton's tyrosine kinase inhibitor approved for several B-cell malignancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.